

Form PTO-1449

Docket Number 549062000200

Application Number 10/723,003

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Jing MA et al.

Filing Date November 26, 2003

Group Art Unit 1642

Mailing Date May 3, 2004

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
LAB ↓	1.	07/26/2001	09/915,746	Ma et al.			
	2.	11/26/2003	10/722,849	Ma			
	3.	06/19/2003	200030113341	Lynch et al.			
	4.	08/07/2003	20030148516	Lyman et al.			
	5.	09/04/2003	2003/0165531	Lynch et al.			
	6.	10/02/2003	2003/0186214	Yan et al.			
	7.	10/23/1990	4,965,195	Namen et al.			
	8.	11/06/1990	4,968,607	Dower et al.			
	9.	09/27/1994	5,350,683	Sims et al.			
	10.	08/13/1996	5,545,806	Lonberg et al.			
	11.	10/29/1996	5,569,825	Lonberg et al.			
	12.	04/29/1997	5,624,821	Winter et al.			
	13.	04/29/1997	5,625,126	Lonberg et al.			
	14.	05/27/1997	5,633,425	Lonberg et al.			
	15.	08/26/1997	5,661,016	Lonberg et al.			
	16.	10/14/1997	5,677,171	Hudziak et al.			
	17.	01/06/1998	5,705,157	Greene			
	18.	01/20/1998	5,710,248	Grose			
	19.	12/01/1998	5,843,423	Lyman et al.			
	20.	02/20/2001	6,190,655	Lyman et al.			
	21.	02/27/2001	6,194,551	Idusogie et al.			
	22.	09/18/2001	6,291,661	Graddis et al.			
	23.	01/01/2002	6,335,429	Cai et al.			
	24.	01/29/2002	6,342,611	Weber et al.			
	25.	05/21/2002	6,391,575	Fritz et al.			
	26.	06/04/2002	6,399,061	Anderson et al.			
	27.	09/24/2002	6,455,043	Grillo-Lopez			

EXAMINER:

/Lynn Bristol/

DATE CONSIDERED:

06/29/2006

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

LAB	28.	10/01/2002	6,458,356	Arakawa et al.			
↓	29.	02/18/2003	6,521,740	Sims et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
LAB	30.	05/09/1990	EP 0 367 566	Europe				
↓	31.	12/11/1991	EP 0 460 846	Europe				
↓	32.	11/18/1999	WO 99/58572	WIPO				
↓	33.	06/06/2002	WO 02/43478	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
LAB	34.	Angal, S. et al. (1993). "A Single Amino Acid Substitution Abolishes The Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <i>Mol. Immunol.</i> 30(1):105-108.
↓	35.	Banchereau, J. et al. (1998). "Dendritic Cells and the Control of Immunity," <i>Nature</i> 392:245-252.
↓	36.	Banchereau, J. et al. (2000). "Immunobiology of Dendritic Cells," <i>Ann Rev. Immunol.</i> 18:767-811.
↓	37.	Bastin, P. et al. (1996). "A Novel Epitope Tag System to Study Protein Targeting and Organelle Biogenesis in <i>Trypanosoma Brucei</i> ," <i>Mol. & Biochem. Parasitology</i> 77:235-239.
↓	38.	Brodowicz, T. et al. (2001). "Anti-Her-2/neu Antibody Induces Apoptosis in Her-2/neu Overexpressing Breast Cancer Cells Independently From p53 Status," <i>Br. J. Cancer</i> 85(11):1764-1770.
↓	39.	Budiardjo, I et al. (1999). "Biochemical Pathways of Caspase Activation During Apoptosis," <i>Ann. Rev. Cell Dev. Biol.</i> 15:269-290.
↓	40.	Burstein, H. et al. (2003). "Trastuzumab and Vinorelbine as First-Line Therapy for Her2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm," <i>J. Clin. Oncol.</i> 21(15):2889-2895.
↓	41.	Carter, P. et al. (1992). "Humanization of an Anti-p185 ^{Her2} Antibody for Human Cancer Therapy," <i>PNAS USA</i> 89:4285-4289.
↓	42.	Chen, C-F. et al. (1998). "Expression Vector Containing an N-Terminal Epitope Tag for <i>Dictyostelium Discoideum</i> ," <i>BioTechniques</i> 25(1):22 and 24.

EXAMINER: /Lynn Bristol/	DATE CONSIDERED: 06/29/2006
--------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

LAB	43.	Choudhury, A. et al. (1997). "Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia," <i>Blood</i> 89(4):1133-1142.
	44.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> pp. 77-96.
	45.	Coloma, M. J. et al. (1992). "Novel Vectors for the Expression of Antibody Molecules Using Variable Regions Generated by Polymerase Chain Reaction," <i>J. Immunol. Methods</i> 152:89-104.
	46.	Coloma, M. J. et al. (1997). "Design and Production of Novel Tetravalent Bispecific Antibodies," <i>Nat. Biotech</i> 15:159-163.
	47.	Cosman, D. et al. (1984). "Cloning, Sequence and Expression of Human Interleukin-2 Receptor," <i>Nature</i> 312:768-771.
	48.	Cosman, D. et al. (1986). "High Level Stable Expression of Human Interleukin-2 Receptors in Mouse Cells Generates Only Low Affinity Interleukin-2 Binding Sites," <i>Mol. Immunol.</i> 23(9):935-941.
	49.	Coulie, P. et al. (1992). "Precursor Frequency Analysis of Human Cytolytic T Lymphocytes Directed Against Autologous Melanoma Cells," <i>Int. J. Cancer</i> 50:289-297.
	50.	Crombet-Ramos, T. et al. (2002). "Antiproliferative, Antiangiogenic and Proapoptotic Activity of H-R3: A Humanized Anti-EGFR Antibody," <i>Int. J. Cancer</i> 101:567-575.
	51.	Di Nicola, M. et al. (1998). "Human Dendritic Cells: Natural Adjuvants in Antitumor Immunotherapy," <i>Cytokines Cell Mol. Therapy</i> 4:265-273.
	52.	Fiers, W. et al. (1978). "Complete Nucleotide Sequence of SV40 DNA," <i>Nature</i> 273:113-120.
	53.	Fong, C. L. et al. (2000). "Dendritic Cells in Cancer Immunotherapy," <i>Ann. Rev. Immunol.</i> 18:245-273.
	54.	Fong, C.L. et al. (2001). "Altered Peptide Ligand Vaccination With Flt3 Ligand Expanded Dendritic Cells For Tumor Immunotherapy," <i>Proc. Natl. Acad. Sci USA</i> 98(15):8809-8814.
	55.	Fong, C.L. et al. (2002). "Generation of Potent and Specific Cellular Immune Responses Via In Vivo Stimulation of Dendritic Cells by pNGVL3-hFLex Plasmid DNA and Immunogenic Peptides," <i>Gene Therapy</i> 9:1127-1138.
	56.	Galfrè, G. et al. (1981). "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods In Enzymol.</i> 73:3-46.
	57.	Genbank Accession No. X06659 (or 001459) last updated February 10, 1999, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 2 pages.
	58.	Genbank Accession No.U03858. last updated July 19, 1994, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 2 pages.
✓	59.	Genbank Accession No. U04806. last updated May 11, 1994, located at < http://www.ebi.ac.uk/cgi-bin/emblfetch?style=html > on February 17, 2004, 2 pages.

EXAMINER:	/Lynn Bristol/	DATE CONSIDERED:	06/29/2006
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

LAB	60.	Genbank Accession No.U29874. last updated February 29, 1996, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 3 pages.
	61.	Gilliland, D. G. et al. (2002). "Role of FLT3 in Leukemia," <i>Curr. Opin. Hematol.</i> 9:274-281.
	62.	Gluzman, Y. (1981). "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," <i>Cell</i> 23:175-182.
	63.	Green, L. et al. (1998). "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes," <i>J. Exp. Med.</i> 188:483-495.
	64.	Grütter, M. G. (2000). "Caspases: Key Players in Programmed Cell Death," <i>Curr. Opin. Structural Biol.</i> 10:649:655.
	65.	Hannum, C. et al. (1994). "Ligand for FLT3/FLK2 Receptor Tyrosine Kinase Regulates Growth of Haematopoietic Stem Cells and Is Encoded by Variant RNAs," <i>Nature</i> 368:643-648.
	66.	Harbury, P. B. et al. (1993). "A Switch Between two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants," <i>Science</i> 262:1401-1407.
	67.	Hatakeyama, M. et al. (1989). "A Restricted Cytoplasmic Region of IL-2 Receptor β Chain Is Essential for Growth Signal Transduction but Not For Ligand Binding and Internalization," <i>Cell</i> 59:837-845.
	68.	Herbst, R.S. et al. (2001). "IMC-C225, an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, For Treatment of Head and Neck Cancer," <i>Expert Opin. Biol. Ther.</i> 1(4):719-732.
	69.	Jakobovits, A.(1998). "Production and Selection of Antigen-Specific Fully Human Monoclonal Antibodies from Mice Engineereered with Human Ig Loci," <i>Adv. Drug Del. Rev.</i> 31:33-42.
	70.	Karlsson, R. et al. (1991). "Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Anaylitical System," <i>J. Immunol. Methods</i> 145:229-240.
	71.	Kawakami, Y. et al. (1989). " IL-4 Regulates IL-2 Induction of Lymphokine-Activated Killer Activity From Human Lymphocytes," <i>The J. of Immunol.</i> 142(10):3452-3461.
	72.	Kozbor, D. et al. (1983). "The Production of Monoclonal Antibodies From Human Lymphocytes," <i>Immunol. Today</i> 4(3):72-79.
	73.	Luckow, V. A. et al. (1988). "Trends in the Development of Baculovirus Expression Vectors," <i>BioTechnology</i> 6:47-55.
	74.	Lyman, S. D. et al. (1993). "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," <i>Cell</i> 75:1157-1167.
	75.	Marks, J. D. et al. (1991). "By-Passing Immunization Human Antibodies from V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.
✓	76.	McMahan, C. et al. (1991). "A Novel IL-1 Receptor, Cloned from B Cells By Mammalian Expression, Is Expressed in Many Cell Types," <i>EMBO J.</i> 10:2821-2832.

EXAMINER: /Lynn Bristol/	DATE CONSIDERED: 06/29/2006
--------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

LAB	77.	Nagelkerken, B. et al. (1997). "A Novel Epitope Tag for the Detection of rabGTPases," <i>Electrophoresis</i> 18:2694-2698.
	78.	Okayama, H. et al. (1983). "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <i>Mol. Cell. Biol.</i> 3:280-289.
	79.	Oláh, Z. et al. (1994). "A Cloning and e-Epitope-Tagging Insert for the Expression of Polymerase Chain Reaction-Generated cDNA Fragments in <i>Escherichia Coli</i> and Mammalian Cells," <i>Analytical Biochem</i> 221:94-102.
	80.	Péron, J-M. et al. (1998). "FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells," <i>The J. of Immunol.</i> 161:6164-6170.
	81.	Pitti, R. M. et al. (1996). "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> 271(22):12687-12690.
	82.	Prickett, K. S. et al. (1989). "A Calcium-Dependent Antibody for Identification and Purification of Recombinant Proteins," <i>BioTechniques</i> 7(6):580-584.
	83.	Prodromou, C. et al. (1992). "Protocol Recursive PCR: A Novel Technique for Total Gene Synthesis," <i>Protein Eng.</i> 5(8):827-829.
	84.	Rosnet, O. et al. (1993). "Human FLT3/FLK2 Gene: cDNA Cloning and Expression in Hematopoietic Cells," <i>Blood</i> 82(4):1110-1119.
	85.	Rosnet, O. et al. (1996). "Human FLT3/FLK2 Receptor Tyrosine Kinase is Expressed at the Surface of Normal and Malignant Hematopoietic Cells," <i>Leukemia</i> 10:238-248.
	86.	Rüdiger, M. et al. (1997). "Epitope Tag-Antibody Combination Useful for the Detection of Protein Expression in a Prokaryotic and Eukaryotic Cells," <i>BioTechniques</i> 23(1):96-97.
	87.	Shimizu, M. et al. (1996). "A Trial to Kill Tumor Cells Through Fas (CD95)-Mediated Apoptosis <i>In Vivo</i> ," <i>Biochem. Biophys. Res. Commun.</i> 228(2):375-379.
	88.	Small, D. et al. (1994). "STK-1, the Human Homolog of Flk-2/Flt-3, is Selectively Expressed in CD34+ Human Bone Marrow Cells and is Involved in the Proliferation of Early Progenitor /Stem Cells," <i>PNAS USA</i> 91:459-463.
	89.	Spiridon, C. I. (2002). "Targeting Multiple Her-2 Epitopes With Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line <i>In Vitro</i> and <i>In Vivo</i> ," <i>Clinical Cancer Res.</i> 8:1720-1730.
	90.	Tolbert, L. M. et al. (1998). "Antibody to Epitope Tag Induces Internalization of Human Muscarinic Subtype 1 Receptor," <i>J. Neurochem.</i> 70(1):113-119.
	91.	Tseng, C-P. et al. (1996). "Functional Expression and Characterization of the Mouse Epitope Tag-Protein Kinase C Isoforms, α , β I, β II, γ , δ and ϵ ," <i>Gene</i> 169:287-288.
✓	92.	Urdal, D. L. et al. (1984). "Lymphokine Purification by Reversed-Phase High-Performance Liquid Chromatography," <i>J. of Chromatog.</i> 296:171-179.

EXAMINER: /Lynn Bristol/	DATE CONSIDERED: 06/29/2006
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 549062000200

Application Number 10/723,003

Applicant

Jing MA et al.

Filing Date November 26, 2003

Group Art Unit 1642

Mailing Date May 3, 2004

LAB	93.	Wang, L-F. et al. (1996). "BTag: A Novel Six-Residue Epitope Tag for Surveillance and Purification of Recombinant Proteins," <i>Gene</i> 169(1):53-58.
	94.	Watson, J. D. eds. et al. (1987). "The Fine Structure of Bacterial and Phage and Genes," <i>In Molecular Biology of The Gene</i> , 4th Edition, The Benjamin /Cummings Pub. Co. Inc. pp. 224-225.
	95.	Xie, L. Y et al. (1998). "Epitope Tag Mapping of the Extracellular and Cytoplasmic Domains of the Rat Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor," <i>Endocrinology</i> 139(11):4563-4567.
↓	96.	Zitvogel, L. et al. (1996). "Therapy of Murine Tumors with Tumor Peptide-Pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-Associated Cytokines," <i>J. Exp. Med.</i> 183:87-97.

EXAMINER:

/Lynn Bristol/

DATE CONSIDERED:

06/29/2006

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitution for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Application Number	10/723,003		
Filing Date	11/26/2003		
First Named Inventor	Jing Ma		
Group Art Unit	1653		
Examiner Name	Unknown		
Attorney Docket Number	047630-0301		
Sheet	1	of	1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAB	A1	5554512		Lyman et al.	09-10-1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (If known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LAB	A2	Van Spriel et al., "Immunotherapeutic perspective for bispecific antibodies." Immunology Today, 21(8): 391-397, 2000.	
	A3	International Search Report for international application No. PCT/US2004/17765.	

Examiner Signature	/Lynn Bristol/	Date Considered	06/29/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.